World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
27175
World Ranking
19013
National Ranking
9478

John M. Vierling publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where John M. Vierling sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 395 publications — 37th percentile

37% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

John M. Vierling D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where John M. Vierling sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 75 D-Index — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

John M. Vierling is affiliated with Baylor College of Medicine in the United States. Their research primarily focuses on medicine, with an emphasis on hepatology, epidemiology, surgery, pulmonary and respiratory medicine, and oncology. Within these fields, Vierling has significantly contributed to multiple subfields and topics related to liver diseases and treatments.

The main topics of their work include:

  • Liver Disease Diagnosis and Treatment
  • Liver Diseases and Immunity
  • Pediatric Hepatobiliary Diseases and Treatments
  • Liver Disease and Transplantation
  • Gallbladder and Bile Duct Disorders
  • Organ Transplantation Techniques and Outcomes
  • Hepatitis C virus research

Vierling has published extensively, with a concentration of works appearing in key journals such as:

  • Journal of Hepatology
  • Gastroenterology
  • The American Journal of Gastroenterology
  • Alimentary Pharmacology & Therapeutics
  • Clinical Transplantation

Some recent publications featuring their contributions include:

  • Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis (2023), New England Journal of Medicine
  • A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis (2024), New England Journal of Medicine
  • A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA (2021), Journal of Hepatology
  • A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease (2023), Journal of Hepatology
  • Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group (2022), Journal of Hepatology

Frequent collaborators in Vierling's research include:

  • Cynthia Levy
  • Christopher L. Bowlus
  • Gideon M. Hirschfield
  • Marlyn J. Mayo
  • Kris V. Kowdley

Vierling's scholarly output encompasses over 150 publications in medicine, with 51 specifically in hepatology, reflecting a targeted expertise in liver-related conditions and treatment modalities.

Best Publications

  • Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection

    Bruce R. Bacon;Stuart C. Gordon;Eric Lawitz;Patrick Marcellin

  • Diagnosis and management of autoimmune hepatitis.

    Michael P. Manns;Albert J. Czaja;James D. Gorham;Edward L. Krawitt

  • Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

    Vlad Ratziu;Vlad Ratziu;Stephen A. Harrison;Sven Francque;Pierre Bedossa

  • Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

    Paul Y Kwo;Eric J Lawitz;Jonathan McCone;Eugene R Schiff

  • Diagnosis and Management of Autoimmune Hepatitis in Adults and Children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases.

    Cara L. Mack;David Adams;David N. Assis;Nanda Kerkar

  • Risk Factors and Comorbidities in Primary Biliary Cirrhosis: A Controlled Interview-Based Study of 1032 Patients

    M. Eric Gershwin;Carlo Selmi;Carlo Selmi;Howard J. Worman;Ellen B. Gold

  • Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection

    Marc Bourlière;Stuart C. Gordon;Steven L. Flamm;Curtis L. Cooper

  • Changing nomenclature for PBC: from ‘cirrhosis’ to ‘cholangitis’

    Ulrich H W Beuers;M Eric Gershwin;Robert G Gish;Pietro Luigi Invernizzi

  • Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence

    Fred Poordad;Eugene R. Schiff;John M. Vierling;Charles Landis

  • Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

    Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  • Hepatitis B virus S mutants in liver transplant recipients who were reinfected despite hepatitis B immune globulin prophylaxis.

    Marc G. Ghany;Brick Ayola;Federico G. Villamil;Robert G. Gish

  • Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, multicentre phase 2 trial

    Kris V Kowdley;Eric Lawitz;Israel Crespo;Tarek Hassanein

  • Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial

    Ira M. Jacobson;Robert S. Brown;Bradley Freilich;Nezam Afdhal

  • Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial

    Mark Sulkowski;Christophe Hezode;Jan Gerstoft;John M Vierling

  • Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

    Robert J. Fontana;Hie Won L. Hann;Robert P. Perrillo;John M. Vierling

  • Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

    Andrew J. Muir;Mitchell L. Shiffman;Atif Zaman;Boris Yoffe

  • Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: final long-term results.

    Eugene Schiff;Cjing Lung Lai;Stephanos Hadziyannis;Peter Nuehaus

  • 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients

    Marla C Dubinsky;Eric A Vasiliauskas;Hardeep Singh;Maria T Abreu

  • Effectiveness of Elbasvir and Grazoprevir Combination, With or Without Ribavirin, for Treatment-Experienced Patients With Chronic Hepatitis C Infection

    Paul Kwo;Edward J. Gane;Cheng Yuan Peng;Brian Pearlman

  • Crohn’s ileitis after liver transplantation from a living related donor with Crohn’s disease

    K A Papadakis;R Matuk;M T Abreu;E A Vasiliauskas

Frequent Co-Authors

John A. Goss
John A. Goss Baylor College of Medicine
Eric Lawitz
Eric Lawitz The University of Texas at Austin
Ira M. Jacobson
Ira M. Jacobson New York University
Bruce R. Bacon
Bruce R. Bacon Saint Louis University
Gideon M. Hirschfield
Gideon M. Hirschfield University Health Network
M. Eric Gershwin
M. Eric Gershwin University of California, Davis
Stefan Zeuzem
Stefan Zeuzem Goethe University Frankfurt
Andrew J. Muir
Andrew J. Muir Duke University
Michael P. Manns
Michael P. Manns Hannover Medical School
David Jones
David Jones Newcastle University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in healthcare but unsure about Medical School, online degrees can offer flexible and rewarding career paths. For example, earning an online nutrition degree allows you to explore dietetics, wellness coaching, and public health education from anywhere.

Those seeking leadership roles may consider online mha programs that develop expertise in hospital and healthcare management. These programs prepare you for administrative positions, policy development, or health services management.

Nurses looking to advance can find flexible options through rn to bsn without clinicals programs, allowing registered nurses to gain a Bachelor of Science in Nursing entirely online, often at an accelerated pace.

For nursing professionals who want to reach the top of their field, the shortest dnp programs online offer a direct route to advanced practice, leadership, and faculty roles.

These online pathways make it easier to balance work, study, and other commitments—helping you enter, advance, or specialize within the field of healthcare.

Best Scientists Citing John M. Vierling

Trending Scientists

Recently Published Articles